BRIEF published on 07/15/2026 at 17:50, 3 months 15 days ago Medincell Aligns Debt Maturity with Revenue Growth Expectations Revenue Growth Non-dilutive Financing Olanzapine LAI UZEDY® Debt Maturity Alignment
PRESS RELEASE published on 07/15/2026 at 17:45, 3 months 15 days ago Informations privilégiées / Autres communiqués Medincell aligne son profil de dette avec sa croissance attendue, renforce sa position financière avec des financements non dilutifs et une maturité de dette prolongée, annonce Christophe Douat de Medincell Croissance Financement Non Dilutif Medincell Maturité De Dette Profil De Dette
PRESS RELEASE published on 07/15/2026 at 17:45, 3 months 15 days ago Inside Information / Other news releases Medincell aligns debt maturity with expected revenue growth trajectory by securing €28 million non-dilutive new bank loans and early repayment of €20 million EIB credit facility tranche Revenue Growth Debt Maturity Medincell Bank Loans EIB Credit Facility
BRIEF published on 06/16/2026 at 21:21, 4 months 14 days ago Medincell: Key Results and Initiatives for 2025-2026 Innovation Treasury R&D Royalties Medincell
BRIEF published on 06/16/2026 at 21:21, 4 months 14 days ago Medincell : Résultats et initiatives clés pour 2025-2026 Innovation R&D Trésorerie Royalties Medincell
PRESS RELEASE published on 06/16/2026 at 21:16, 4 months 14 days ago Informations privilégiées / Communiqué sur comptes, résultats Medincell publie ses résultats financiers annuels consolidés pour l'exercice 2025-2026, mettant en avant la solidité opérationnelle et la transition vers un modèle reposant sur l'innovation et les revenus récurrents Résultats Financiers Innovation Revenus Récurrents Medincell Exercice 2025-2026
BRIEF published on 05/21/2026 at 19:29, 5 months 9 days ago EMA Accepts Teva's Application for Long-Acting Schizophrenia Treatment Schizophrenia Treatment Teva Pharmaceuticals EMA Approval Olanzapine Injectable Long-acting Formulation
BRIEF published on 05/21/2026 at 19:29, 5 months 9 days ago L'EMA accepte la demande de Teva pour un traitement de la schizophrénie à action prolongée Traitement De La Schizophrénie Teva Pharmaceuticals Approbation De L'EMA Olanzapine Injectable Formule À Action Prolongée
PRESS RELEASE published on 05/21/2026 at 19:24, 5 months 9 days ago Informations privilégiées / Autres communiqués L'EMA accepte le dossier de demande de mise sur le marché de l'Olanzapine LAI par Teva pour le traitement de la schizophrénie. Technologie de libération prolongée SteadyTeq(TM) utilisée Schizophrénie Teva EMA Olanzapine LAI SteadyTeq
PRESS RELEASE published on 05/21/2026 at 19:24, 5 months 9 days ago Inside Information / Other news releases European Medicines Agency accepts Teva's Marketing Authorization Application for Olanzapine Long-Acting Injectable to treat schizophrenia in adults. Teva and Medincell announce EMA acceptance for innovative treatment option Schizophrenia Medincell Olanzapine Teva EMA
Published on 10/30/2026 at 23:35, 45 minutes ago Prospect Ridge Announces Closing of Critical Metals Flow-through Unit Private Placement
Published on 10/30/2026 at 23:30, 50 minutes ago Revolve Enters into Definitive Agreement to Acquire Three Project, 6 MW Battery Storage Portfolio in Ontario
Published on 10/30/2026 at 20:47, 3 hours 33 minutes ago CoTec Holdings Corp. Comments on Share Trading
Published on 10/30/2026 at 19:00, 5 hours 20 minutes ago Electric Royalties Ltd. Announces Application for Warrant Extension
Published on 10/30/2026 at 15:30, 8 hours 50 minutes ago Bluejay Diagnostics Announces 1-for-4 Reverse Stock Split
Published on 10/30/2026 at 22:49, 1 hour 31 minutes ago EQS-Adhoc: STRATEC SELLS LOSS-MAKING BUSINESS, RECOGNIZES IMPAIRMENTS, AND AMENDS GUIDANCE
Published on 10/30/2026 at 18:38, 5 hours 42 minutes ago EQS-Adhoc: Starcom Holding AD publishes Interim Q3 2026 Financial Report
Published on 10/30/2026 at 23:00, 1 hour 20 minutes ago BIOPHYTIS REPORTS FIRST- HALF 2026 RESULTS AND PROVIDES AN UPDATE ON ITS STRATEGY
Published on 10/30/2026 at 23:00, 1 hour 20 minutes ago Biophytis publie les résultats du premier semestre 2026 et fait le point sur sa stratégie
